HOME >> BIOLOGY >> NEWS
Halfway human

Delson recreated the shape of SM3's skull using coordinates from some 200 points on its surface. He did the same for 23 other specimens-11 H. erectus, 10 modern H. sapiens, and 2 archaic H. sapiens. With this information, his computer program arranged the specimens according to their similarity, placing SM3 just about squarely between the erectus and modern humans-while even the archaic H. sapiens fell in among the erectus specimens.

Next, Delson told the computer that there were categories called "erectus", "sapiens" and "archaic", and asked it to find features that would force known members of each group closer together. Again the program lumped archaic H. sapiens in with the erectus specimens. And when Delson asked the computer to categorise the unknown SM3 it still ended up floating between the two main groups, though a bit closer to the erectus cluster. Delson therefore feels comfortable designating SM3 as an erectus, albeit a strange one. He suggests three possible explanations for her odd looks. She could have been an aberrant individual. She could be a member of a hitherto unknown population of Indonesian H. erectus with bulging foreheads. Or, he acknowledges, she could represent "a population evolving in the direction of modern humans". The last explanation is music to the ears of multiregionalists. "That is very daring for him to say," says Wolpoff. "If you thought Homo sapiens began in Africa, as I know [Delson] does, then something in Indonesia has no business evolving in that direction."

But SM3 doesn't even have to be the long-awaited missing link to be troublesome. The finding that she fits so poorly into existing species categories seems to highlight an ongoing problem in paleoanthropology. The experts still argue over what constitutes H. erectus, an enormous group that has been called "the muddle in the middle" because it spans more than a million years and includes many specimens, from Indonesia, Asia and Africa, that don't neces
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
10-Apr-2001


Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Climate change plus human pressure caused large mammal extinctions in late Pleistocene
2. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
3. Most recent common ancestor of all living humans surprisingly recent
4. Wildlife Conservation Society hosts public symposium on human-wildlife diseases
5. Bronfenbrenner book sums up human development
6. No role for simian virus 40 in human pleural mesotheliomas
7. Sugar-coated sea urchin eggs could have sweet implications for human fertility
8. Serotonin metabolites in mollusks suggest pathways for human therapies
9. Wrapping a memory with an experience, capacity for recollection detected in non-human species
10. Viral suspect for amphibian decline traced to human spread through bait
11. Recent evolution at a single gene may have brought down heart disease risk in some human groups

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Halfway human

(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: